Intellia Therapeutics (NTLA) to Release Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Intellia Therapeutics to post earnings of ($1.21) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.29. The business had revenue of $28.94 million during the quarter, compared to analyst estimates of $15.60 million. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Stock Up 2.6 %

NTLA stock traded up $0.57 during midday trading on Tuesday, hitting $22.90. 513,516 shares of the company traded hands, compared to its average volume of 1,557,613. The business has a 50 day simple moving average of $24.31 and a 200-day simple moving average of $25.40. Intellia Therapeutics has a twelve month low of $19.37 and a twelve month high of $40.98. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -4.17 and a beta of 1.81.

Analysts Set New Price Targets

NTLA has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. BMO Capital Markets lifted their price objective on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Truist Financial reaffirmed a “buy” rating and issued a $120.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 24th. Finally, Wedbush reissued a “neutral” rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.25.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.